Descriptors of multidrug-resistant TB deaths in Ethiopia.

Ethiopia RR/MDR-TB TB-related mortality drug-resistant TB deaths rifampicin-resistant TB

Journal

Public health action
ISSN: 2220-8372
Titre abrégé: Public Health Action
Pays: France
ID NLM: 101624961

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 30 05 2023
accepted: 16 07 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: ppublish

Résumé

Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented. Les décès liés à la TB multirésistante chez les patients ayant reçu des médicaments antituberculeux de seconde ligne en Éthiopie ont été analysés. Respectivement 38/704 (5,4%) et 44/995 (4,4%) décès ont été identifiés dans deux cohortes (2015 et 2022). Dans la cohorte 2015, la malnutrition sévère était moins fréquente, les taux de traitement antérieur étaient trois fois plus élevés, l’hypokaliémie était plus fréquente, et l’utilisation du test Xpert

Autres résumés

Type: Publisher (fre)
Les décès liés à la TB multirésistante chez les patients ayant reçu des médicaments antituberculeux de seconde ligne en Éthiopie ont été analysés. Respectivement 38/704 (5,4%) et 44/995 (4,4%) décès ont été identifiés dans deux cohortes (2015 et 2022). Dans la cohorte 2015, la malnutrition sévère était moins fréquente, les taux de traitement antérieur étaient trois fois plus élevés, l’hypokaliémie était plus fréquente, et l’utilisation du test Xpert

Identifiants

pubmed: 38077723
doi: 10.5588/pha.23.0030
pmc: PMC10703136
doi:

Types de publication

Journal Article

Langues

eng

Pagination

123-125

Informations de copyright

© 2023 The Union.

Références

PLoS One. 2021 May 6;16(5):e0250804
pubmed: 33956812
PLoS One. 2021 Jun 28;16(6):e0253848
pubmed: 34181701
Clin Infect Dis. 2021 Nov 2;73(9):e3563-e3571
pubmed: 33372989
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28696239
Arch Public Health. 2020 Jul 31;78:69
pubmed: 32760587
PLoS One. 2015 Mar 19;10(3):e0119332
pubmed: 25790076

Auteurs

E Tesema (E)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

Z G Dememew (ZG)

USAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.

D G Datiko (DG)

USAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.

A Gebreyohannes (A)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

Y Molla (Y)

USAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.

A Tefera (A)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

G Gizatie (G)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

T Bogale (T)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

M Million (M)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

P G Suarez (PG)

Management Sciences for Health, Global Health Systems Innovation, Arlington, VA, USA.

M M Aseressa (MM)

Management Sciences for Health, Global Health Systems Innovation, Arlington, VA, USA.

D Jerene (D)

KNCV Tuberculosis Foundation, The Hague, The Netherlands.

M Biru (M)

United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.

Classifications MeSH